SMMTSummit Therapeutics Inc.
Price
-10%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, the market undecided.
The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF (as defined in Part I, Item I Business, Company Overview, Ivonescimab) compound into a single molecule. On December 5, 2022, the Company entered into the License Agreement with Akeso, Inc. and its affiliates (collectively, “Akeso”) pursuant to which the Company has in-licensed intellectual property rights related to ivonescimab (as amended, the “License Agreement”).
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Oct 19, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 28, 2026, Summit Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with AstraZeneca Holdings B.V. (the “Investor”), a subsidiary of AstraZeneca plc, for the issuance and sale by the Company of 108,955.3686 shares (the “Preferred Shares”) of the …Material agreement entered · Form 8-K
- Sep 15, 2026On September 15, 2026, Summit Therapeutics Inc. (the "Company") issued a press release announcing that updated overall survival results from the global Phase III HARMONi clinical trial were presented today at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (“WCLC 2026”)Other event · Form 8-K
- Sep 14, 2026On September 13, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced that updated data, including overall survival, from the randomized, double-blind Phase III HARMONi-2 trial, is being presented at the International Association for the Study of Lung Cancer’s 2026 World …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.